Image of a laboratory worker at Scorpion's biologics contract manufacturing facility in Texas


Get To Know Us

Biologics & New Modalities

Scorpius BioManufacturing is a CDMO focused on mammalian, microbial, and cell therapies. We provide a broad array of biologics manufacturing, analytical and R&D services to pharmaceutical and biotech companies to advance their discoveries and deliver new therapies to patients from our San Antonio facilities, with a focus on offering services using American-made equipment, reagents, and materials.


Our biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies and beyond in support of commercial manufacturing programs. By integrating analytical methods development, process development, cGMP manufacturing product characterization, and QC release testing, we can efficiently develop a client-specific clinical manufacturing solution that enables a faster path to clinical trials and product commercialization.

Analytical Testing

Our analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines, and advanced therapies. Test methods can be qualified or validated for use in measuring product quality and consistency in lot characterization and release, as well as stability testing programs. A variety of analytical methods are available, including compendial and client-specific/custom assays. Our stability programs are conducted under ICH guidelines and are designed to meet both client and regulatory requirements.

Clinical-Scale Facility

Scorpius has completed construction on a new clinical-scale biomanufacturing facility at the VelocityTX Innovation Center in San Antonio, Texas, which is fully operational. The facility offers ~2,000 sq. ft. of process and analytical development space and ~8,600 sq. ft. of cGMP-compliant cleanroom manufacturing space. Biomanufacturing capabilities include upstream and downstream processing up to 500 L scale for mammalian and cell therapy-based products and up to 200 L scale for microbial-based products.

Experience & Capabilities

Scorpius has experienced, client-facing program and project managers who are collaborative, transparent and strong in communication, and act as a seamless extension of your operation, offering data insights based on a range of assays along with services to support your products. Our growth will facilitate the integration of bioanalytical services and biomanufacturing.


Scorpius is an entirely American company. From our ownership and locations to the major equipment (such as Pall Allegro™ bioreactors), consumables and reagents that we use, we strive to create a development chain that is American-sourced.